Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases

European Journal of Pharmacology

Volumn 617, Issue 1-3, 2009, Pages 84-89

  Ekinci, Deniz ^a   Beydemir, Şükrü ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Antibiotic; Atherosclerosis; Inhibition; Organophosphate; Paraoxonase

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ORNIDAZOLE; RIFAMYCIN; SCAVENGER; TEICOPLANIN; TOBRAMYCIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; HYDROLYSIS; HYPERTHYROIDISM; LIPID OXIDATION; PRIORITY JOURNAL; PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS;

AMMONIUM SULFATE; ANTI-BACTERIAL AGENTS; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; DEAE-DEXTRAN; HUMANS;

EID: 68549126724     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.048     Document Type: Article

References (41)

1. Abbott C., Mackness M., Kumar S., Boulton A., and Durrington P. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1812-1818
2. Alici H.A., Ekinci D., and Beydemir Ş. Intravenous anesthetics inhibit human paraoxonase-i (pon1) activity in vitro and in vivo. Clin. Biochem. 41 (2008) 1384-1390
3. Ashani Y., and Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol. Sci. 77 (2004) 358-367
4. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004) 1304-1316
5. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - a possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
6. Bergmeier C., Siekmeier R., and Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 50 (2004) 2309-2315
7. Bradford M.M. A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Chait A., Han C.Y., Oram J.F., and Heinecke J.W. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. J. Lipid. Res. 46 (2005) 389-403
9. Ciftci M., Beydemir S., and Ekinci D. Effects of some drugs on enzymatic activity of glucose 6-phosphate dehydrogenase from chicken erythrocytes in vitro. Asian J. Chem. 20 (2008) 2189-2196
10. Coban T.A., Beydemir S., Gulcin I., and Ekinci D. Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo. Biol. Pharm. Bull. 30 (2007) 2257-2261
11. Deakin S., and James R. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 107 (2004) 435-447
12. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscl. Throm. Vas. 21 (2001) 473-480
13. Ekinci D., and Beydemir S. Effect of some analgesics on paraoxonase-1 purified from human serum 21 4 (2009) 1034-1039
14. Ekinci D., Beydemir S., and Ali{dotless}m Z. Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol. Rep. 59 (2007) 580-587
15. Fortmann S.P., Haskell W.L., and Williams P.T. Changes in plasma high density lipoprotein cholesterol after changes in cigarette use. Am. J. Epidemiol. 124 (1986) 706-710
16. Gaidukov L., and Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44 (2005) 11843-11854
17. Gan K., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
18. Getz G.S., and Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr. Opin. Lipidol. 15 (2004) 261-267
19. Gulcin I., Beydemir S., Coban T.A., and Ekinci D. The inhibitory effect of dantrolene sodium and propofol on 6-phosphogluconate dehydrogenase from rat erythrocyte. Fresen. Environ. Bull. 17 (2008) 1283-1287
20. James R.W., and Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 37 (2004) 1986-1994
21. Laemmli D.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227 (1970) 680-683
22. Laplaud P., Dantoine T., and Chapman J. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin. Chem. Lab. Med. 36 (1998) 431-441
23. Li W.F., Costa L.G., and Furlong C.E. Serum paraoxonase status-a major factor in determining resistance to organophosphates. J. Toxicol. Environ. Health. 40 (1993) 337-346
24. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., and Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10 (2000) 767-779
25. Lineweaver H., and Burk D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56 (1934) 658-666
26. Mackness, B., Mackness, M., Aviram, M., Paragh, György, 2008. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Edited . Published by Springer, P.O. Box 17, 3300 AA Dordrecht, The Netherlands.
27. Mackness M., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density-lipoprotein. FEBS Lett. 286 (1991) 152-154
28. Mackness M.I., Durrington P.N., and Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease [Hyperlipidaemia and cardiovascular disease]. Curr. Opin. Lipidol. 15 (2004) 399-404
29. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., and Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radical Biol. Med. 38 (2005) 153-163
30. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
31. Nishio E., and Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236 (1997) 289-293
32. Pla A., Rodrigo L., Hernandez A.F., and Gil Lopez F.O. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem-Biol. Interact. 167 (2007) 63-70
33. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., Shih D.M., Lusis A.J., Navab M., and Fogelman A.M. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 542-547
34. Renault F., Chabrière E., Andrieu J.P., Dublet B., Masson P., and Rochu D. Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J. Chromatogr. B. 836 (2006) 15-21
35. Rosenblat M., Karry R., and Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 187 (2006) 74-81
36. Rozenberg O., Shih S.D., and Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181 (2005) 9-18
37. Scheffler E., Huber L., Fruhbis J., Schulz I., Ziegler R., and Dresel H.A. Alteration of plasma low density lipoprotein from smokers. Atherosclerosis 82 (1990) 261-265
38. Shadnia S., Azizi E., Hosseini R., Khoei S., Fouladdel S., Pajoumand A., Jalali N., and Abdollahi M. Evaluation of oxidative stres and genotoxicity in organophosphorus insecticide formulators. Hum. Exp. Toxicol. 9 (2005) 439-445
39. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
40. Sinan S., Kockar F., and Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglycoside derived antibiotics. Biochimie 88 (2006) 565-574
41. Watson A., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., and Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891